Introduction
Interferon (IFN) is a cytokine that has a variety of biological properties, including immunomodulatory and antiproliferative actions. 1 IFNa-2b and IFN-b have been widely applied for the treatment of patients with chronic hepatitis C, and there is a growing body of evidence that IFNs reduce the incidence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C 2,3 and the intrahepatic recurrence of HCC after effective treatment, 4, 5 and there are some dramatic reports demonstrating HCC regression after IFN therapy. 6, 7 Although these clinical reports suggest that IFNs may be useful in the treatment of HCC patients, the results of in vitro experiments regarding the effects of IFNs on liver cancer cells are still under discussion. [8] [9] [10] Extracellular signal-regulated kinase (ERK1/2) and AKT are intracellular signaling molecules which have pivotal roles in the regulation of the motility, 11 cell cycle, 12 apoptosis, 13, 14 and growth 15 of a variety of cells, including hepatocytes. The blockade of these intracellular signaling molecules has recently emerged as a new approach to cancer treatment, by targeting key molecules specifically relevant to carcinogenesis. 16 This prompted us to explore the possible involvement of ERK1/2 and AKT signaling molecules in the regulation of the cellular proliferation of liver cancer cells when challenged with IFNs.
Materials and methods

Materials
Human recombinant IFNa-2b and fibroblast IFN-b were obtained from Schering-Plough (Osaka, Japan) and Toray (Tokyo, Japan), respectively. Anti-signal transducer and activator of transcription (STAT-1; Tyr701), AKT (Ser473), p38 mitogen-activated protein Background. Interferon (IFN) has been reported to reduce the incidence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C and the recurrence of HCC after effective treatment. We examined the effect of IFNs on the proliferation and the signaling pathways of human HCC cells. Methods. Cellular proliferation was examined by a modified 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT) assay. Activities of signaling molecules were evaluated by Western blot analysis. Results. Cellular growth was not significantly modulated by IFNa-2b or by IFN-b, even though the HCC cells expressed the IFN receptors. However, extracellular signal-regulated kinase (ERK)1/2 was activated by treatment with IFNa2b, and both ERK1/2 and AKT were activated by treatment with IFN-b, implying a possible role in resistance to IFNs. Contrary to our expectations, inhibition of mitogen-activated ERK-regulating kinase (MEK) or phosphatidylinositol-3-OH kinase (PI3K) did not modulate the proliferation of HCC cells. Also, abrogation of the ERK1/2 and AKT signaling pathways did not affect cell-cycle arrest at the G1/S phase caused by IFNa-2b. Conclusions. IFNa-2b and IFN-b activated ERK1/2 and/or AKT independently of modulating the proliferation of HCC cells and the cell-cycle machinery. A signal transduction-based approach for HCC treatment needs to focus on other possible signaling molecules besides ERK1/2 and AKT when challenged with IFNs.
kinase (MAPK; Thr180/Tyr182), and c-Jun-N-terminal kinase (JNK; Thr183/Tyr185) antibodies, detecting only the phosphorylated residues, and phosphorylationindependent antibodies for STAT-1, ERK1/2, p38MAPK, and JNK were purchased from Cell Signaling Technology (Beverly, MA, USA). An antibody specific for ERK1/2, phosphorylated at the Thr202/Tyr204 residues, and an anti-b-actin antibody were purchased from Sigma (St. Louis, MO, USA). U0126 (a mitogenactivated ERK-regulating kinase [MEK] inhibitor) and LY294002 (a phosphatidylinositol-3-OH [PI3K] inhibitor) were purchased from Calbiochem-Novabiochem (San Diego, CA, USA). These two compounds were dissolved in dimethyl sulfoxide (Me 2 SO), with the final concentration never exceeding 0.1%. Secondary antimouse and anti-rabbit horseradish peroxidase antibodies were obtained from Amersham Pharmacia Biotechnology (Piscataway, NJ, USA).
Cell lines and tissue culture
Human liver cancer cells (Hep3B, HLF, Huh6, and PLC/PRF/5) and epidermoid cancer cells (A431) were cultured in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% fetal bovine serum and penicillin/streptomycin, at 37°C in a 5% CO 2 incubator.
Cell proliferation
Cellular proliferation was assessed by modified 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assays (Cell Counting Kit-8; Dojindo, Kumamoto, Japan) following the supplier's protocol. The experiments were repeated at least six times.
Flow cytometry
Cell pellets treated with IFNa-2b were washed with phosphate-buffered saline (PBS) containing 1% fetal bovine serum, fixed in 70% ethanol, and stained with 0.5 mg/ml propidium iodide (Sigma, St. Louis, MO, USA), containing 3 Kunitz RNase (Nippon Gene, Tokyo, Japan); then analysis was performed with a flow cytometer (EPICS-XL; Beckman Coulter, Miami, FL, USA).
Total protein preparation and Western blotting
Total protein preparation from cells and Western blotting were performed as described previously, with minor modifications. 17 
Reverse transcription-PCR (RT-PCR)
Total RNA was prepared from cells using Isogen (Nippon Gene). Reverse transcription-polymerase chain reaction (RT-PCR) was performed using an RNA LA PCR kit (Takara Bio, Ohtsu, Japan) following the supplier's instructions. Briefly, 1 mg of total RNA with 20 ml of a reaction mixture, consisting of 10 mM TrisHCl (pH 8.3), 50 mM KCl, 5 mM MgCl 2 , 1 mM dNTP mixture, 20 units of RNase inhibitor, 5 units of myeloblastosis virus-derived reverse transcriptase, and 2.5 mM random 9 mers was incubated at 30°C for 10 min, and 42°C for 30°C min, heated at 99°C for 5 min, and then cooled to 5°C for 5 min.
For PCR, the following oligonucleotides were synthesized (Cosmo Biotechnology, Tokyo, Japan) and used as primers: IFN AR1(sense, 5¢-CTTTCAAGTTCA GTGGCTCCACGC-3¢; antisense, 5¢-TCACAGGCGT GTTTCCAGACTG-3¢); IFNAR2 (sense, 5¢-GAAGG TGGTTAAGAACTGTGC-3¢; antisense, 5¢-CCCGCT GAATCCTTCTAGGACGG-3¢). PCR was carried out for 30 cycles (denaturing at 94°C for 30 s and annealing at 58°C for IFNAR1, and at 54°C for IFNAR2, respectively, for 30 s, and extension at 72°C for 1.5 min) in 80 ml of a reaction mixture consisting of 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 2.5 mM MgCl 2 , 2 units of Takara Taq polymerase, 20 mM of primers, and 20 ml of the cDNA. The PCR products were electrophoresed on 2% agarose gel.
Statistical analysis
Data values were expressed as means ± SE. The signals were quantified using the Scion image program (Scion, Frederick, Malyland, USA). The MTT assay data were analyzed, using the paired t-test, to assess differences between experimental groups. Statistical significance was inferred at P < 0.05.
Results
Expression of IFN receptors
First, we examined the expression of the IFN receptors in four human liver cancer cell lines by RT-PCR analysis. Although the RT-PCR analysis we employed was semiquantitative, IFNAR1 was equally expressed in all cell lines. However, the expression levels of IFNAR2 appeared to be variable among the cell lines, demonstrating strong expression in HLF and PLC/PRF/ 5 cells, and weak expression in Hep3B and Huh6 cells (Fig. 1) .
Effects of IFNa-2b and IFN-b on the proliferation of liver cancer cells
Because IFNs have been demonstrated to inhibit the growth of a variety of cancer cells, 18, 19 we evaluated whether IFNa-2b and IFN-b could modulate the proliferation of liver cancer cells. Hep3B, HLF, Huh6, and PLC/PRF/5 cells were incubated with increasing doses of IFNa-2b and IFN-b for 48 h. Neither IFNa-2b nor IFN-b significantly inhibited the growth of the liver cancer cells, except when 3000 U/ml of IFN, which is over the clinically achievable level of IFN, 20 was administered to the cells ( Fig. 2A,C) . When the cells were treated with 1000 U/ml of IFNa-2b and IFN-b for longer periods, the cellular growth was not significantly modified (Fig. 2B, D) . The growth of A431, a cell line sensitive to IFNs, 21 was inhibited when it was treated with IFNs ( Fig. 2A-D) , substantiating the idea that the IFNs we applied to the cells were biologically active. These findings indicate that human liver cancer cells are resistant to the growth-inhibitory effect of IFNs. 
Activation of STAT-1 in liver cancer cells after treatment with IFNa-2b and IFN-b
Because Janus kinase (JAK)/STAT signaling molecules are essential for full responses to most cytokines, including IFNs, 22 we tested whether STAT-1 could be activated in liver cancer cells after the treatment with IFNs. The phosphorylation of STAT-1 was upregulated in a dose-dependent manner when Hep3B and HLF cells were stimulated with increasing doses of IFNa-2b for 30 min (Fig. 3A) . Similar results were obtained in Huh6 and PLC/PRF/5 cells (data not shown). When HLF cells were treated with 1000 U/ml of IFN-b, the phosphorylation of STAT-1 peaked at 30 min and decayed thereafter, presumably by the action of turningoff mechanisms, including suppressors of cytokine signaling (SOCS) 23 ( Fig. 3B) . Similar results were obtained in Hep3B, Huh6, and PLC/PRF/5 cells (data not shown). These results indicate that liver cancer cells have functional signal transduction machineries upon stimulation with IFNs, although they are resistant to IFNs.
Differential activation of ERK1/2 and AKT in liver cancer cells after treatment with IFNa-2b and IFN-b
In order to explore the mechanism of how the liver cancer cells resisted the IFNs, we focused on ERK1/2 and AKT, which have been demonstrated to be responsible for chemoresistance to various compounds. 24 At the basal level, Hep3B and HLF cells demonstrated higher phosphorylation levels of ERK1/2 compared to Huh6 and PLC/PRF/5 cells (Fig. 4A) . When the time course of ERK1/2 activation by IFNa-2b was evaluated, the phosphorylation of ERK1/2 peaked 15 min after treatment with 1000 U/ml of IFNa-2b (Fig.  4B) . When HLF cells were treated with increasing doses of IFNa-2b for 15 min, ERK1/2 was activated mostly in a dose-dependent manner (Fig. 4B) . The ERK1/2 activation was not repeated in Hep3B, Huh6, and PLC/ PRF/5 cells (Fig. 4B and data not shown) , implying that ERK1/2 is activated by IFNa-2b in a cell-type-specific fashion. Although we also evaluated the activation of p38MAPK and JNK, employing phosphorylationspecific antibodies for each molecule, neither p38MAPK nor JNK was phosphorylated after the treatment with 1000 U/ml of IFNa-2b (data not shown) or IFN-b (Fig. 4C) .
AKT was not significantly activated after treatment with IFNa-2b in any liver cancer cells tested (Fig.  4B and data not shown) . When HLF cells were treated with IFN-b, both ERK1/2 and AKT were activated, peaking 15 min after dosing with 1000 U/ml of IFN-b (Fig. 4D) . Neither ERK1/2 nor AKT was significantly activated by IFN-b in Hep3B, Huh6, or PLC/PRF/5 cells (data not shown), suggesting, again, that the activation of ERK1/2 and AKT by IFN-b is a celltype-specific event. 0 100U/ml 500U/ml 1000U/ml 3000U/ml 6000U/ml 0 100U/ml 500U/ml 1000U/ml 3000U/ml 6000U/ml IFNa-2bx15min 
Evaluation of upstream molecules relevant to the activation of ERK1/2 and AKT induced by IFNs
When HLF cells were pretreated with a MEK inhibitor, U0126, the phosphorylation of ERK1/2 induced by IFNa-2b and IFN-b was totally abrogated, although the total expression levels of ERK1/2 were not affected (Fig. 5A) . When the cells were pretreated with a PI3K inhibitor, LY294002, the phosphorylation of AKT induced by IFN-b was totally abolished (Fig. 5B) . These results revealed that IFNs activate ERK1/2 and AKT in a MEK-dependent and PI3K-dependent manner, respectively.
The role of STAT-1 in the activation of ERK1/2 and AKT induced by IFNa-2b and IFN-b
As the next step, we explored whether STAT-1 was responsible for the activation of ERK1/2 and AKT induced by IFNa-2b and IFN-b. The phosphorylation of STAT-1 induced by IFNa-2b was not significantly modulated by pretreatment with U0126, when the phosphorylation levels of STAT-1 were corrected to the expression levels of total STAT-1 and b-actin (Fig. 6, lanes  1 to 3) , thus implying that STAT-1 activity is regulated by IFNa-2b independently of ERK1/2. By contrast, the phosphorylation of STAT-1 induced by IFN-b was partially inhibited by pretreatment with U0126 (Fig. 6 , lanes 4 to 6) and LY294002 (Fig. 6, lanes 7 to 11) . These results demonstrate that the activation of STAT-1 induced by IFN-b, but not that induced by IFNa-2b, is, in part, dependent upon ERK1/2 and AKT.
Effects of IFNa-2b on cell-cycle machinery
We further investigated the effect of IFNa-2b on the cell-cycle machinery in liver cancer cells. The cell cycle was arrested in the G1/S phase after treatment with IFNa-2b (Fig. 7) . Because activated ERK1/2 has been demonstrated to have an important role in the regulation of the cell cycle, 12 we then determined the involvement of ERK1/2 in the G1/S arrest induced by IFNa-2b. Pretreatment with U0126 did not significantly modulate the G1/S arrest (Fig. 7) , indicating that IFNa-2b induced cell-cycle arrest at the G1/S phase in an ERK1/2-independent fashion. lanes 1 to 3) . The phosphorylation of STAT-1 induced by 1000 U/ml of IFN-b was, in part, inhibited by pretreatment with 10 mM U0126 (lanes 4 to 6) and LY294002 (lanes 7 to 11) prior to treatment with IFN-b
ERK1/2 and AKT are not involved in the regulation of the cellular growth by IFNs
Finally, we examined whether the activation of ERK1/2 and AKT induced by IFNa-2b and IFN-b could be involved in the regulation of the proliferation of liver cancer cells. The proliferation of HLF cells when pretreated with U0126 followed by IFNa-2b was almost identical to that when the cells were treated with U0126 alone (Fig. 8A) . The effect of MEK inhibition when the cells were treated with IFN-b was also not significant (Fig. 8B) . When the cells were pretreated with LY294002, followed by treatment with IFN-b, the inhibitory effect on cellular growth by LY294002 alone was not significantly modified (Fig. 8C) . Finally, when the cells were pretreated with both U0126 and LY294002 prior to IFN-b challenge, the cellular growth was not further modulated compared to that when they were pretreated with LY294002 (Fig. 8C) .
These results suggest that ERK1/2 and AKT activities do not appear to be linked to the regulation of cellular proliferation by IFNs.
Discussion
IFNs have been shown to reduce the incidence of preneoplastic foci and cancer 25, 26 in rodent liver cancer models. In in vitro experiments, IFNs have been reported to inhibit the growth of a variety of cancer cells, including multiple myeloma, 18 ovarian cancer, 19 and liver cancer cells. 8, 9 One of the mechanisms of the growth inhibitory effect of IFNs in these cells involves apoptosis, the elucidation of which has so far included the induction of Apo2L/TRAIL 18 and p53, 27 the activation of caspases, 19 and the downregulation of c-Met. 28 By contrast, there are some reports demonstrating that the growth of liver cancer cells was not affected and apoptosis was not observed when physiologically achievable doses of IFNs, which are between 500 IU/ml and 1000 U/ml, 21 were added to the cells. 10 These conflicting results regarding the sensitivity of liver cancer cells to IFNs may be derived from the different experimental conditions, including the presence or absence of serum, the difference of IFNs between IFN-a, and IFNb, 9, 29 and the diversity of liver cancer cells utilized in those studies. When we treated liver cancer cells with IFNa-2b under serum-free conditions, cellular growth was not affected (data not shown) and neither IFNa-2b nor IFN-b revealed growth inhibition even when 3000 U/ml of IFN, which is over the clinically achievable level, 20 was applied to the liver cancer cells, and the cell lines in our study are representative of human liver cancer cells. Therefore, we believe that human liver cancer cells are resistant to IFNs in our experimental conditions. Based on the above observations, we examined the mechanism of liver cancer cell resistance to IFNs. In our study, the IFN receptors, IFNAR1 and IFNAR2, were expressed on the liver cancer cells, in agreement with previous reports. 8 STAT-1, a major signaling molecule located downstream of IFN receptors, 22 was phosphorylated at the Tyr701 residue upon stimulation with IFNs. Although constitutively active SOCS has been reported as one mechanism of resistance to IFN-a in chronic myeloid leukemia cells, 30 our data indicate that the IFNAR1/IFNAR2 and STAT-1 axis is intact in liver cancer cells.
We observed that IFNa-2b arrested the cell cycle at the G1/S phase in liver cancer cells independently of the inhibition of cellular growth and induction of apoptosis. This is not surprising, because a discrepancy between these two events has been reported in the literature. 31 Our preliminary data suggested that the G1/S arrest induced by IFNa-2b may be mediated via the upregulation of p27 KIP1 (unpublished data). Although ERK1/2 activity has been connected to the cell-cycle arrest and upregulation of p27 KIP1 in other cellular systems, 32 the activation of ERK1/2 was not involved in the cell-cycle arrest in our system. In addition, previous reports regarding the molecules responsible for the G1/ S phase arrest induced by IFNs differ, including no involvement of p21 WAF1 or p27 KIP1 , 33 and the involvement of the downregulation of cyclin D1 and the upregulation of p21 WAF1 . 34 Thus, the players responsible for the G1/S arrest and signal transduction pathways leading to the cell-cycle arrest by IFNs appeared to be distinct, depending on the cellular context.
IFNs have been shown to activate ERK1/2 in myeloma cells 35 and liver cancer cells. 28 In agreement with these reports, we observed that IFNs activated ERK1/2 in human liver cancer cells in a cell-type-specific manner. We further demonstrated that ERK1/2 was acti- , and 96 h after HLF cells were treated with 1000 U/ml of IFNa-2b alone, 10 mM U0126 alone, and pretreated with 10 mM U0126 followed by treatment with 1000 U/ml of IFNa-2b. B MTT assays were performed after HLF cells were treated with 10 mM U0126, 1000 U/ml of IFNb, and both of these compounds for 96 h. C MTT assays were performed after HLF cells were pretreated with 10 mM LY294002 (Ly) or simultaneously with Ly and 10 mM U0126, followed by administration of 1000 U/ml of IFN-b for 96 h vated by IFNa-2b in a MEK-dependent manner. It has been reported that IFN-a activated the MEK/ERK signaling pathway in a close relationship with apoptosis in epidermoid cancer cells, and that the ERK signaling pathway has a role in cellular proliferation either in a positive 15 or in a negative manner. 36 In our cellular context, however, the MEK/ERK signaling pathway was not involved in the regulation of cellular proliferation or apoptosis. The role (s) of ERK1/2 activated by IFNs in our cellular system therefore remains unsolved.
The PI3K/AKT signaling pathway has a pivotal role in cellular proliferation, 15 protection from apoptosis, 14 and chemoresistance. 24 In addition to growth factors, including epidermal growth factor (EGF) and hepatocyte growth factor (HGF), 37 IFNs have been demonstrated to activate PI3K/AKT molecules, promoting the survival of a variety of cells. 38, 39 Based on our observation that IFN-b activated AKT via PI3K, we examined whether AKT was involved in the resistance of liver cancer cells to IFN-b. Contrary to our expectations, the blockade of the PI3K/AKT signaling pathway did not enhance the sensitivity of the cells to IFN-b. With these findings taken together, we conclude that human liver cancer cells showed resistance to IFNs by ERK1/2 and AKT-independent mechanisms. The resolution of this issue will open a new treatment avenue for HCC.
We further investigated the relationship between STAT-1 and ERK1/2, and that between STAT-1 and AKT in the signaling machinery of IFNs. The direct association of STAT-1 and ERK1/2, 40 the ERKdependent phosphorylation of STAT-1, 41 and the PI3K/AKT-dependent phosphorylation of STAT-1 42 has been demonstrated in the literature. When we pretreated HLF cells with U0126 and LY294002, the phosphorylation of STAT-1 was partially inhibited by either treatment, implying that the activation of STAT-1 by IFN-b is mediated by the MEK/ERK and PI3K/AKT signaling pathways. By contrast, the inhibition of MEK did not modulate the phosphorylation of STAT-1 when induced by IFNa-2b, suggesting that STAT-1 is acti- vated by IFNa-2b independently of the MEK/ERK signaling pathway. Significant effort has been made recently to enhance the efficiency of IFNs for the treatment of cancer, including IFN treatment with retinoic acid 43 and paclitaxel. 44 However, a growth-inhibitory effect of these combination treatments has been observed only in a subset of cancer cells. In order to achieve a satisfactory effect of IFNs for cancer therapy, especially for HCC, exploitation of the target molecules responsible for resistance to IFNs will open a new avenue of cancer therapy for HCC patients.
